

PAGE 01
#17
Response
PATENT
787444-2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)

Examiner: G. Kishore)

John R. Lau, W. Blair Geho)
George H. Schnedeker)

Group Art Unit: 1615)

Serial No.: 09/313,828)

RECEIVED

Filed: May 15, 1999)

APR 10 2002

OFFICE OF PETITIONS

For: **TARGETED LIPOSOMAL
DRUG DELIVERY SYSTEM**)

**RESPONSE TO OFFICE
ACTION**)

Docket No.: 787444-2001)

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In the Office Action mailed on April 6, 2001, the Examiner made final the restriction requirement relating to claims 1-4, 6, 29, 31 and 37-41, withdrawing these claims from consideration. Claims 5, 7-8, 30 and 32-36 were rejected by the Examiner.

REMARKS

The Applicants respectfully request the Examiner to consider their following response to the points raised by the Examiner in the above-described April 6, 2001 Office Action.

The name of the chemical compound shown in Figure 2 and described in claim 13 is Cr-bis[N-(2,6-diisopropylphenyl)carbamoylmethyl] iminodiacetic acid]. This compound has not yet become the polynuclear complex shown in Figure #4.